PMV Pharmaceuticals Inc. announced a new chief operating officer.
Winston Kung also will serve as chief financial officer for the Cranbury-based company.
Kung was previously vice president of business development and global alliances at Celgene, and held the position of chief business officer at Celgene Cellular Therapeutics.
He will help manage the development of PMV Pharma’s mutant p53 restoration drug pipeline, which got a boost in February, when the company completed a $74 million series B financing round.
“Winston’s track record of deal-making and his financial acumen and leadership will be instrumental as we develop drugs that use a unique mechanism of action to restore mutated p53 proteins to their pivotal role in defending against cancer,” said CEO and President David Mack.
Prior to joining Celgene, Kung held senior positions at Citigroup’s Global Healthcare Investment Banking group and at Lehman Bros.’ Global Mergers and Acquisition group, where he oversaw public and private financings, mergers, acquisitions, spin-outs and financial advisory engagements.
“I joined PMV Pharma’s stellar leadership team to help advance the company’s world-class research and emerging pipeline,” Kung said. “Like many people, I have family and friends who have been impacted by cancer. PMV is developing drugs that may dramatically improve cancer treatment, and I’m excited to be a part of the exceptional team driving this effort.”
Kung has also led multiple transactions as part of Genentech’s and Amgen’s Business and Corporate Development groups.
